Bristol-Myers Squibb and Boston Medical Center collaborate to investigate markers of immuno-oncology response and resistance
The comprehensive, multi-dimensional study will place an emphasis on uncovering mechanisms associated with lack of response to Immuno-Oncology (I-O) therapies
Serum Institute’s partner NeuClone develops mAb for breast cancer indication
NeuClone's Perjeta (pertuzumab) biosimilar is partnered with Serum Institute of India (Serum). Under the partnership, NeuClone and Serum are developing ten biosimilars for global markets.